CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety.
Sekar discusses how this trial will be carried out and what the data gained from it will be used for.
CSE:CBII
Market: CSE
Market Cap: $9.6 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: CB2 Insights partners with fully licensed Colombia-based...
CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) CEO Prad Sekar tells Proactive that the Ontario-based company is partnering with licensed producer FCM Global S.A.S. Sekar says FCM Global is one of the only fully licensed Colombian cannabis producers where CB2 will support its medical cannabis...
on 12/04/2019
2 min read
Prev article
2 min read